Can I Take Ashwagandha With Mounjaro? A Women's Guide to the Real Interaction

What the Interaction Actually Is (and Is Not)

There is no documented pharmacokinetic clash between ashwagandha and Mounjaro. Tirzepatide is a dual GIP/GLP-1 receptor agonist administered subcutaneously once weekly; it is not metabolized by the cytochrome P450 system in a way that ashwagandha's withanolides could meaningfully disrupt [1]. So if you were worried about one drug changing the blood level of the other, that specific worry is not well-supported by current evidence.

The real concern is pharmacodynamic. Both substances act on the same downstream biology: cortisol regulation, blood glucose, and, in women specifically, thyroid hormone levels. When two agents push overlapping levers, the clinical effects can add up in ways that are hard to predict and harder to monitor.

How Tirzepatide Works in Women

Tirzepatide activates both GLP-1 and GIP receptors, slowing gastric emptying, reducing appetite, and improving insulin sensitivity [2]. In the SURMOUNT-1 trial, participants on 15 mg tirzepatide lost a mean of 20.9% of body weight over 72 weeks [2]. Women in that trial were not analyzed as a separate subgroup in the primary publication, which is an important evidence gap.

Weight loss itself changes estrogen metabolism, SHBG levels, and insulin sensitivity differently in women than in men, particularly in women with PCOS or those in perimenopause. The compound effect of GLP-1/GIP signaling on female hormonal axes is still being studied.

How Ashwagandha Works

Ashwagandha (Withania somnifera) is an adaptogenic herb whose active constituents are primarily withanolides. Its best-documented human effects include:

• Lowering serum cortisol
• Modulating thyroid function (primarily raising T3 and T4)
• Potentially increasing testosterone and DHEA-S
• Modest reductions in fasting blood glucose

A 2019 double-blind RCT in 60 adults published in Medicine found that 240 mg/day of ashwagandha root extract for 60 days reduced serum cortisol by 22.2% compared to placebo [3]. A separate 2012 RCT in the Indian Journal of Psychological Medicine using 300 mg twice daily found a 27.9% reduction in serum cortisol [4]. These are not trivial effects.

Why Cortisol Is the Overlooked Link

Cortisol is a counterregulatory hormone. It raises blood glucose by stimulating hepatic gluconeogenesis and opposing insulin action. If you are taking Mounjaro to manage blood glucose or body weight and you add something that lowers cortisol significantly, the net glucose-lowering effect may be larger than your prescriber planned for.

This is not theoretical scaremongering. Hypoglycemia risk with GLP-1/GIP agonists used as monotherapy is genuinely low, but it rises when other glucose-modifying factors are added, including weight loss itself, reduced caloric intake, and, potentially, cortisol suppression. Women with adrenal insufficiency or HPA axis dysregulation (more common in perimenopause and in women with a history of chronic stress or hypothalamic amenorrhea) face a higher baseline risk here.

The Perimenopause Angle

During perimenopause, cortisol dysregulation is common. Estrogen withdrawal removes a buffer on HPA axis reactivity, and many perimenopausal women experience elevated evening cortisol, disrupted sleep, and central weight gain that is specifically driven by cortisol-insulin crosstalk [5]. Mounjaro is being used in this population, sometimes off-label for weight management, without diabetes.

If you are perimenopausal and already on ashwagandha for sleep or stress, adding Mounjaro means your care team needs to know both are on your list. The interaction is not a reason to automatically stop ashwagandha, but it is a reason to check fasting glucose more frequently in the first 8-12 weeks of combined use.

What to Monitor

• Fasting glucose at baseline, 4 weeks, and 8 weeks after starting both together
• Symptoms of hypoglycemia: shakiness, sweating, confusion, rapid heartbeat
• Blood pressure (ashwagandha may lower systolic BP modestly; tirzepatide can also lower BP through weight loss)

The Thyroid Signal: Especially Relevant for Women

Thyroid disease affects women at roughly 5 to 8 times the rate of men [6]. Hypothyroidism, Hashimoto's thyroiditis, and postpartum thyroiditis are common in the exact demographic most likely to be combining ashwagandha and Mounjaro.

Ashwagandha has a documented thyroid-stimulating effect. A 2018 randomized trial in the Journal of Alternative and Complementary Medicine found that 600 mg/day of ashwagandha root extract for 8 weeks significantly raised serum T3 (by 41.5%) and T4 (by 19.6%) compared to placebo in adults with subclinical hypothyroidism [7]. TSH fell correspondingly.

Why does this matter for Mounjaro users? Two reasons.

If You Have Hypothyroidism

Your levothyroxine dose was titrated to a specific TSH target. Adding ashwagandha could push T3 and T4 higher and TSH lower, making you look biochemically hyperthyroid on paper and potentially prompting a dose reduction that is not actually warranted. If your prescriber does not know about the ashwagandha, they may adjust your thyroid medication based on lab values that do not accurately reflect your thyroid gland's function.

GLP-1 receptor agonists, including the GLP-1 component of tirzepatide, are associated with increased risk of thyroid C-cell tumors in rodent studies, which is why Mounjaro carries a black-box warning for thyroid C-cell tumor risk and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2 [8]. Ashwagandha's thyroid stimulation does not directly address this C-cell risk, but any supplement that changes thyroid lab values adds noise to thyroid monitoring.

If You Have Hashimoto's

Ashwagandha is sometimes marketed as beneficial for autoimmune thyroid disease. The evidence is thin. The 2018 Sharma trial enrolled adults with subclinical hypothyroidism, not confirmed Hashimoto's, and the sample was small (n=50) [7]. Extrapolating those results to an autoimmune thyroid context requires caution. If you have Hashimoto's and want to try ashwagandha, get a TSH, free T3, and free T4 before starting, and recheck at 8 weeks.

PCOS, Testosterone, and the Androgen Question

PCOS affects an estimated 8 to 13% of reproductive-age women [9]. Many women with PCOS are prescribed tirzepatide off-label for insulin resistance and weight management. Ashwagandha is popular in the PCOS community for its purported cortisol and stress benefits, and some preliminary data suggests it may raise testosterone and DHEA-S.

Here is the framework for thinking about this by PCOS subtype:

Insulin-resistant PCOS (the most common type): Tirzepatide directly addresses the insulin resistance. Ashwagandha's cortisol reduction may provide a small additive benefit. The testosterone question cuts both ways: if androgen levels are already elevated (as they are in most PCOS phenotypes), further testosterone-raising effects from ashwagandha are not necessarily welcome.

Adrenal PCOS (elevated DHEA-S): Ashwagandha may raise DHEA-S further. If you fall into this subtype, ashwagandha is a poor fit regardless of whether you are on Mounjaro.

Post-pill PCOS (temporary after stopping oral contraceptives): The hormonal picture here is already in flux. Adding an adaptogen with androgen-modifying effects while also starting a GLP-1/GIP agonist makes it very difficult to interpret lab trends. Stagger the starts by at least 8 weeks if possible.

A 2015 prospective study in the American Journal of Reproductive Immunology found that ashwagandha raised testosterone and luteinizing hormone in men undergoing fertility treatment, though [10]. Direct evidence in women with PCOS is absent from the peer-reviewed literature as of mid-2025. This is an evidence gap worth naming plainly.

Pregnancy, Lactation, and Contraception

Both tirzepatide and ashwagandha are contraindicated in pregnancy. This is a hard stop.

Tirzepatide is classified as Pregnancy Category not formally assigned under the old FDA system, but current FDA labeling states that animal data showed fetal harm at clinically relevant exposures and that tirzepatide should be discontinued at least 1 month before a planned pregnancy because of its 5-day half-life [8]. If you become pregnant while on Mounjaro, stop it immediately and contact your OB-GYN.

Ashwagandha's use in pregnancy is contraindicated based on traditional medical texts and limited animal data showing abortifacient properties. A 2020 case series and review noted adverse pregnancy outcomes associated with high-dose ashwagandha in animal models [11]. No adequate human pregnancy safety data exists, which means the risk cannot be characterized as zero.

Lactation

Tirzepatide's transfer into breast milk has not been studied in humans. Given the high molecular weight (approximately 4.8 kDa), transfer is expected to be low, but the FDA label does not clear it for use during breastfeeding [8]. Until data exists, most clinicians advise against its use during lactation.

Ashwagandha is present in traditional postpartum formulations in Ayurvedic practice as a galactagogue, but peer-reviewed lactation safety data is absent. The LactMed database notes insufficient data to assess risk [12]. Caution is the appropriate stance.

Contraception Note

If you are of reproductive age and starting Mounjaro, reliable contraception is not optional during treatment. GLP-1/GIP agonists may alter oral contraceptive absorption by slowing gastric emptying; the Mounjaro prescribing information recommends switching to a non-oral contraceptive method or adding a barrier method for at least 4 weeks after each dose escalation [8].

Who This Combination Is Right For (and Who Should Avoid It)

Situations Where Combining May Be Acceptable

• You are postmenopausal, have no thyroid disease, and use ashwagandha specifically for cortisol and sleep support
• Your prescriber reviews your full supplement list and decides the benefit/risk ratio favors continuing
• You have access to regular lab monitoring (TSH, fasting glucose, HbA1c)
• You are not on levothyroxine or any other thyroid medication

Situations That Warrant Extra Caution or Avoidance

• You have hypothyroidism or Hashimoto's and are on levothyroxine
• You have adrenal PCOS with elevated DHEA-S
• You are in perimenopause with significant cortisol or sleep dysregulation that has not yet been clinically characterized
• You are trying to conceive, pregnant, or breastfeeding
• You are on any sulfonylurea or insulin alongside tirzepatide (hypoglycemia risk amplified)
• You have a personal or family history of medullary thyroid carcinoma or MEN2

Practical Guidance: What to Do Right Now

If you are already taking both and have not told your prescriber, tell them at your next visit. Bring the bottle. Tell them the dose and how long you have been taking it. This is not about getting in trouble; it is about making sure your lab results are interpreted correctly.

If you want to start ashwagandha while on Mounjaro:

1. Get baseline labs first: TSH, free T3, free T4, fasting glucose, HbA1c, and blood pressure.
2. Start at the lowest studied dose: 300 mg of a standardized extract (KSM-66 or Sensoril) once daily.
3. Recheck TSH and fasting glucose at 8 weeks.
4. Track symptoms of hypoglycemia and report them promptly.
5. If you are on levothyroxine, tell your prescribing endocrinologist or internist before adding ashwagandha.

On Timing and Dose Separation

There is no pharmacokinetic reason to time ashwagandha separately from your weekly tirzepatide injection. The interaction is pharmacodynamic and cumulative, not a moment-to-moment absorption clash. Dose-separation windows (like the 4-hour rule used for levothyroxine and calcium) do not apply here.

The Evidence Gap: What We Still Do Not Know

No published randomized controlled trial has enrolled women taking tirzepatide and measured the effect of concurrent ashwagandha on glucose control, weight loss outcomes, thyroid function, or cortisol dynamics. Every recommendation in this article, and every recommendation your clinician makes, is based on extrapolating from separate bodies of evidence.

The SURMOUNT program did not collect supplement use data in a way that allows post-hoc analysis of ashwagandha specifically [2]. The Women's Health Initiative did not study GLP-1 agonists. Women have been under-represented in metabolic pharmacology trials for decades, and the intersection of botanical supplement use with newer weight-loss medications is not yet a funded research priority.

That evidence gap means being conservative is reasonable. It does not mean the combination is definitely harmful; it means we do not yet have enough information to confidently say it is not.

Ashwagandha Alternatives That Carry Fewer Overlapping Effects

If your goal with ashwagandha is stress and cortisol support, and you are nervous about the thyroid and androgen effects, a few alternatives have a cleaner interaction profile with tirzepatide:

• Magnesium glycinate (200-400 mg at night): Supports sleep and HPA axis without documented thyroid or androgen effects. No meaningful interaction with tirzepatide identified.
• L-theanine (100-200 mg): Amino acid from green tea with anxiolytic properties; no known glucose or thyroid effects at standard doses.
• Phosphatidylserine (400 mg/day): Has cortisol-blunting data in exercise-induced stress models; not associated with thyroid stimulation.

None of these have been studied alongside tirzepatide in RCTs either, but their mechanisms of action create fewer overlapping concerns with Mounjaro's pharmacodynamics.

Get a TSH and fasting glucose before starting ashwagandha with Mounjaro, and repeat both at 8 weeks. That single monitoring step will catch the most clinically relevant problems before they become harder to sort out.